Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Mirum Pharmaceuticals, Inc. - common stock
(NQ:
MIRM
)
93.80
-2.95 (-3.05%)
Streaming Delayed Price
Updated: 2:55 PM EDT, Sep 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Mirum Pharmaceuticals, Inc. - common stock
< Previous
1
2
3
4
5
6
Next >
Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript
↗
August 12, 2026
LIVMARLI sales surged 46% while management raised full-year guidance to $680M–$700M.
Via
The Motley Fool
Topics
Earnings
Mirum Pharmaceuticals Q2 Earnings Call Highlights
↗
August 05, 2026
Mirum Pharmaceuticals (NASDAQ:MIRM) reported second-quarter net product sales of $176 million and raised its full-year 2026 product sales outlook to $680 million to $700 million, while outlining...
Via
MarketBeat
Topics
Earnings
Mirum Pharmaceuticals (NASDAQ:MIRM) Slides on Wider Loss and Volixibat Delay Despite Revenue Beat
↗
August 05, 2026
Via
Chartmill
Wondering what's happening in today's after-hours session?
↗
August 05, 2026
Via
Chartmill
Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Dips After Q1 Revenue Beat and Guidance Raise, Despite Massive IPR&D Charge
↗
May 06, 2026
Via
Chartmill
Mirum Pharmaceuticals (NASDAQ:MIRM) Reports Q4 2025 Revenue Beat and 2026 Outlook
↗
February 25, 2026
Via
Chartmill
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Embodies the Minervini Growth Momentum Strategy
↗
February 14, 2026
Via
Chartmill
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance
↗
May 27, 2026
Mirum Pharmaceuticals (NASDAQ:MIRM) executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and...
Via
MarketBeat
Mirum Pharma: A Rare Disease Growth Story to Watch
↗
May 20, 2026
Mirum stock pulled back after earnings despite strong growth. Here’s why investors still see upside in the rare disease biotech company
Via
MarketBeat
Penn Capital Unloads 1.13 Million RealReal Shares Following Massive Stock Run-Up
↗
May 07, 2026
This online marketplace connects U.S. consumers with consigned luxury goods, spanning apparel, jewelry, art, and home products.
Via
The Motley Fool
Topics
Artificial Intelligence
Regulatory Compliance
Mirum (MIRM) Q1 2026 Earnings Call Transcript
↗
May 06, 2026
Mirum (MIRM) Q1 2026 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Offers a High-Growth Momentum and Technical Breakout Setup
↗
February 10, 2026
Via
Chartmill
2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term
↗
April 19, 2026
Vertex Pharmaceuticals has given Mirum Pharmaceuticals the blueprint for success in rare diseases.
Via
The Motley Fool
Prediction: Buying This Biotech Stock Today Could Set You Up for Life
↗
April 13, 2026
This small biotech could grow much larger with some good news from its pipeline.
Via
The Motley Fool
Mirum (MIRM) Q2 2025 Earnings Call Transcript
↗
April 01, 2026
Mirum (MIRM) Q2 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Mirum Pharma (MIRM) Earnings Call Transcript
↗
April 01, 2026
Mirum Pharma (MIRM) Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Mirum (MIRM) Q1 2025 Earnings Call Transcript
↗
April 01, 2026
Mirum (MIRM) Q1 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Intellectual Property
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026
↗
March 20, 2026
This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis.
Via
The Motley Fool
Topics
Regulatory Compliance
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position
↗
March 20, 2026
This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.
Via
The Motley Fool
Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy?
↗
March 15, 2026
HealthEquity delivers cloud-based healthcare savings solutions to employers and individuals, with a broad client network across the U.S.
Via
The Motley Fool
Small-Cap Shudder: Russell 2000’s 1.9% Slide Signals Cracks in Economic Resilience
March 05, 2026
NEW YORK — The euphoric "small-cap comeback" that defined the opening weeks of 2026 came to a grinding halt on Thursday. The Russell 2000 index, the primary barometer for American small-cap health,...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Energy
Mirum (MIRM) Q4 2025 Earnings Call Transcript
↗
February 25, 2026
Mirum (MIRM) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
ACM Research’s AI Surge Collides With Export Controls and Chip Spending Cycles
↗
February 25, 2026
Penn Capital initiated a position in ACM Research, which supplies cleaning and plating tools used in advanced semiconductor manufacturing. As AI-driven chip designs grow more complex, precision...
Via
The Motley Fool
Topics
Artificial Intelligence
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition
↗
February 17, 2026
Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma.
Via
The Motley Fool
Topics
Regulatory Compliance
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough
↗
February 17, 2026
Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge
↗
February 17, 2026
This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates.
Via
The Motley Fool
Topics
Regulatory Compliance
Is Mirum Pharmaceuticals on a Strong Path to Profitability?
↗
January 31, 2026
The drugmaker is doing nearly everything else right.
Via
The Motley Fool
Is Mirum Pharmaceuticals About to Soar in 2026?
↗
January 27, 2026
The future looks bright for this high-flying biotech stock.
Via
The Motley Fool
A New Era in Rare Hepatology: The Deep-Dive Analysis of Mirum Pharmaceuticals (MIRM)
January 13, 2026
Date: January 13, 2026 Introduction Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has reached a critical inflection point, evolving from a speculative clinical-stage biotech into a commercial-stage...
Via
PredictStreet
Topics
Economy
Initial Public Offering
3 Top Growth Stocks to Buy in the First Half of 2026
↗
January 13, 2026
Don't wait too long to make a decision on these three stocks.
Via
The Motley Fool
Topics
Artificial Intelligence
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
